None listed
Conditions
Interventions
Group A will receive multi-level BTX injections 6 weeks after the first assessment, group B after 30 weeks.
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosis of cerebral palsy (CP), hemiplegia or diplegia, ability to walk with or without a walking aid, with or without an ankle-foot orthosis; 2. gait characterized by persistent flexion of the hip and knee in mid-stance when walking; 3. age between 4 and 12 years.
Exclusion criteria
Exclusion criteria: 1. BTX treatment in lower extremities 16 weeks before inclusion; 2. Orthopaedic surgery 24 weeks before inclusion; 3. Contra-indication for BTX-A; 4. Contra-indication for general anaesthesia; 5. Severe fixed contractures; 6. Orthopaedic deformities, which have a bad influence walking: 6.1 (Sub)luxation of the hip with a migration index > 50 degrees; 6.2 Hip endorotation contracture > 15 degrees; 6.3 Flexion contracture of knee > 15 degrees; 7. Presence of ataxia of dyskinesia; 8. Other problems which have a negative influence on walking.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Gross Motor Function Measure (GMFM); 2. Energy cost of walking. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Spasticity of the treated muscles; 2. Passive range of motion of lower extremity joints; 3. Edinburgh Visual Gait score (GAIT); 4. Pediatric Evaluation Disability Inventory (PEDI), domain ‘mobility’; 5. Problem score. | — |
Contacts
Public ContactJ.G. Becher
VU University Medical Center, P.O. Box 7057
Outcome results
None listed